Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study ; volume:25 ; number:1 ; day:18 ; month:9 ; year:2023 ; pages:1-11 ; date:12.2023
Arthritis Research & Therapy ; 25, Heft 1 (18.9.2023), 1-11, 12.2023
- Urheber
-
Baraliakos, Xenofon
Heijde, Désirée van der
Sieper, Joachim
Inman, Robert D.
Kameda, Hideto
Li, Yihan
Bu, Xianwei
Shmagel, Anna
Wung, Peter
Song, In-Ho
Deodhar, Atul
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-023-03128-1
- URN
-
urn:nbn:de:101:1-2024020907515823073966
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Baraliakos, Xenofon
- Heijde, Désirée van der
- Sieper, Joachim
- Inman, Robert D.
- Kameda, Hideto
- Li, Yihan
- Bu, Xianwei
- Shmagel, Anna
- Wung, Peter
- Song, In-Ho
- Deodhar, Atul
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study
Andersson lesion in ankylosing spondylitis
Upadacitinib (ankylosierende Spondylitis) : Nutzenbewertung gemäß § 35a SGB V
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Surgical treatment of ankylosing spondylitis deformity
Secukinumab: A Review in Ankylosing Spondylitis
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
ANKHvariants associated with ankylosing spondylitis: gender differences
Atherosclerosis in Egyptian patients with ankylosing spondylitis
Association between ankylosing spondylitis and m6A methylation
Developing mapping algorithms to predict EQ-5D health utility values from Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index among patients with Ankylosing Spondylitis
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study
Andersson lesion in ankylosing spondylitis
Upadacitinib (ankylosierende Spondylitis) : Nutzenbewertung gemäß § 35a SGB V
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Surgical treatment of ankylosing spondylitis deformity
Secukinumab: A Review in Ankylosing Spondylitis
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
ANKHvariants associated with ankylosing spondylitis: gender differences
Atherosclerosis in Egyptian patients with ankylosing spondylitis
Association between ankylosing spondylitis and m6A methylation
Developing mapping algorithms to predict EQ-5D health utility values from Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index among patients with Ankylosing Spondylitis
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study
Andersson lesion in ankylosing spondylitis
Upadacitinib (ankylosierende Spondylitis) : Nutzenbewertung gemäß § 35a SGB V
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Surgical treatment of ankylosing spondylitis deformity
Secukinumab: A Review in Ankylosing Spondylitis
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
ANKHvariants associated with ankylosing spondylitis: gender differences
Atherosclerosis in Egyptian patients with ankylosing spondylitis
Association between ankylosing spondylitis and m6A methylation